Liposomal prostaglandin E1 can reduce inflammatory factors and the incidence of adverse cardiac events for percutaneous coronary intervention
- VernacularTitle:脂质体携载前列腺素E1对冠脉介入治疗后炎症因子的影响
- Author:
Wenhua LIANG
- Publication Type:Journal Article
- Keywords:
Prostaglandin E1;
Percutaneous coronary intervention;
Inflammatory factor
- From:
Journal of Chongqing Medical University
1986;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the inflammatory factors for early use of lipid carriers prostaglandin E1 on percutaneous coronary intervention(PCI).Method:74 patients treated with PCI were randomly divided into experimental and control groups.PGE1 20?g + 40 ml normal saline intravenously,Bid ? 3 d,were used in experimental groups,but not to the patients in the control group.The basis treatment was the same.CRP,IL-6,TNF-? were checked in the pre-operative 1 d,after 2 d,after 5 d,after 4 w,and after 60 d,the early incidence of cardiac events were observed.Results:CRP levels in every patients for two groups increased at 1 d(P0.05).After 5 d～4 w,CRP level in the experimental group were declined than 1 d(P 0.05).Inflammatory factor IL-6,TNF-? and CRP showed the same trend.Conclusions:CRP,IL-6 and TNF-? may have increased in the early stage of post-PCI,and the use of Lipo-PGE1 may be effective in containing the level of inflammatory factors.
